ALSO NOTED: Seattle Genetics to raise cash; Biocancell IIb trial approved;and much more...

> Seattle Genetics plans to raise cash by selling 10 million shares of its stock. Report

> The FDA has given Biocancell Therapeutics an OK to continue a Phase IIb trial on a new bladder cancer drug. Release

> Teva is exploring the possible sale of its animal health division. Release

> Qiagen says that it has won an antitrust ruling in a patent lawsuit with Third Wave Technologies. Release

> Adventrx Pharmaceuticals announced that ANX-530 demonstrated a statistically significant reduction in injection site reactions when compared to Navelbine. Release

> Sanofi and P&G say a collaborative development program for a 150 mg, once-monthly dose of the osteoporosis drug risedronate proved noninferior when compared with a 5 mg daily dose of the drug in a late-stage study. Release

> Is fibromyalgia an ill-gotten label that could only benefit drug companies? Or is it a real disease that needs treatment? Judging by the abrupt rise in prescriptions for the Pfizer drug Lyrica since it was approved for fibromyalgia treatment in June, it's real. But doctors are still arguing. Report

> In an interview with the Financial Times, Johnson & Johnson CEO Bill Weldon (photo) admits to a fascination with technology. Report

> The gig is up, the news is out. Merck and Schering-Plough announced the results of its big ENHANCE trial this morning. Report

And Finally... A UK study led by researchers at Cardiff University suggests that a chemical first found on Easter Island could treat the genetic disorder tuberous sclerosis, which causes tumors to grow in many of the organs of the body. Release

Suggested Articles

Janssen’s BCMA-targeting CAR-T therapy eliminated tumors in 69% of patients with advanced multiple myeloma in a small phase 1 study.

In a study, BMS' CAR-T therapy banished tumors in more than half and shrank tumors in nearly three-quarters of relapsed blood cancer patients.

Novartis unveiled more data showing how its asthma combo QMF149 fared against the standard of care: a combination of the same types of drugs.